Sustaining integrating imatinib and interferon-α into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation.

导出原文传递

翻译打印收藏纠错

作者： Pu,Kuang ^[1] ; Ting,Liu ^[1] ; Ling,Pan ^[1] ; Huanling,Zhu ^[1] ; Yu,Wu ^[1] ; Yuanxin,Ye ^[2] ; Bing,Xiang ^[1] ; Hongbing,Ma ^[1] ; Hong,Chang ^[1] ; Ting,Niu ^[1] ; Xu,Cui ^[1] ; Chuan,He ^[1] ; Jianjun,Li ^[1] ; Jie,Ji ^[1] ; Jie,Huang ^[1] ; Tian,Dong ^[1] ; Yang,Dai ^[1] ; Xiaojun,Lu ^[2] ; Shenglan,Qing ^[3] ; Huaxin,Wu ^[4] ; Xiaogong,Liang ^[4] ; Xiaoyu,Wang ^[5] ; Chunnong,Wu ^[6]

作者单位： a Department of Hematology, Hematologic Research Laboratory , West China Hospital of Sichuan University , Chengdu , PR China ; ^[1] b Department of Laboratory Medicine , West China Hospital of Sichuan University , Chengdu , PR China ; ^[2] c Department of Hematology , People's Hospital of Deyang , Deyang , PR China ; ^[3] d Department of Hematology , Central Hospital of Mianyang , Mianyang , PR China ; ^[4] e Department of Hematology , the 3rd People's Hospital of Chengdu , Chengdu , PR China ; ^[5] f Department of Hematology , the First Hospital of Liangshan , Xichang , PR China. ^[6]

关键词 Imatinib Philadelphia chromosome positive acute lymphoblastic leukemia interferon-α long-term survival maintenance therapy